Shots: Moderna has reported the robust results of its ongoing P-I study that demonstrated mRNA-1273 at (25-, 100- & 250-mcg dose levels) induced anti–SARS-CoV-2 immune responses in all participants with no trial-limiting safety concerns. These results were published in NEJM All participants seroconverted by the 15-day mark. Post two vaccinations, @57day, geometric mean titers exceeded […]Read More
Shots: The companies reported the selection of DC for VIR-2703 (ALN-COV) targeting SARS-CoV-2 genome and intend to meet US FDA & other regulatory authorities for IND filing with a plan to commence human studies by the end of 2020 In Oct, 2017, Alnylam and Vir entered into an exclusive license agreement to develop and commercialize […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
